Trial for Treatment Refractory Trigeminal Neuralgia

Summary

The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.

Timeline

Start

2019-06-25

Primary completion

2023-05-11

Completion

2023-05-11

Outcome

Outcome not reported

Stopped (Business): “Strategic decision to discontinue the study based on adjusted clinical development plan. This decision is not based on any safety concerns.”

Drugs

Indications